December 23, 2021
Life Sciences
  • Novavax and AstraZeneca announced that its COVID-19 vaccine is effective in generating an immune response against the Omicron variant. Yesterday, Novavax said early data from its booster and adolescent studies showed “broad cross-reactivity” against Omicron and other circulating variants from two shots, and that responses increased with a third dose six months later. In trials, the shot has shown up to 90.4 per cent efficacy. This morning, AstraZeneca announced that a booster shot of its initial two-dose vaccine regimen successfully neutralized the omicron variant in an Oxford study. (Articles here, here, and here)